142 related articles for article (PubMed ID: 38745323)
1. The usage and costs of national drug price-negotiated anticancer medicines in a first-tier city in Northeast China: a study based on health insurance data.
Li BX; Wang YQ; Yi YY; Zhou N; Lv ZX; Ma R; Li X; Yuan N
BMC Public Health; 2024 May; 24(1):1309. PubMed ID: 38745323
[TBL] [Abstract][Full Text] [Related]
2. Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China.
Mingge X; Jingyu W; Qi L; Zhe Z; Qing R
Inquiry; 2023; 60():469580231170729. PubMed ID: 37171066
[TBL] [Abstract][Full Text] [Related]
3. The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data.
Yang Y; Zhang Y; Wagner AK; Li H; Shi L; Guan X
J Glob Health; 2023 Aug; 13():04083. PubMed ID: 37566690
[TBL] [Abstract][Full Text] [Related]
4. Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study.
Cai L; Tao T; Li H; Zhang Z; Zhang L; Li X
J Glob Health; 2022 Dec; 12():11016. PubMed ID: 36527382
[TBL] [Abstract][Full Text] [Related]
5. Access to innovative anticancer medicines in China: a national survey on availability, price and affordability.
Li W; Lu W; Chen H; Zhang C; Wang M; Zheng F; Wu HH; Wan GW; Yang Q; Ye L
BMJ Open; 2024 Apr; 14(4):e077089. PubMed ID: 38670605
[TBL] [Abstract][Full Text] [Related]
6. Impact of medical insurance access negotiation on the utilization of innovative anticancer drugs in China: an interrupted time series analysis.
Li C; Zhu J; Shan L; Zhou Y; Liu G; Zhu H; Wu Q; Cui Y; Kang Z
BMC Health Serv Res; 2024 Jan; 24(1):90. PubMed ID: 38233857
[TBL] [Abstract][Full Text] [Related]
7. Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis.
Huang C; Ung COL; Wushouer H; Bai L; Li X; Guan X; Shi L
Int J Health Policy Manag; 2022 Aug; 11(8):1489-1495. PubMed ID: 34273922
[TBL] [Abstract][Full Text] [Related]
8. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China.
Zhang Y; Wushouer H; Han S; Fu M; Guan X; Shi L; Wagner A
BMJ Glob Health; 2021 Jul; 6(7):. PubMed ID: 34266848
[TBL] [Abstract][Full Text] [Related]
9. Availability, Price and Affordability of Anticancer Medicines: Evidence from Two Cross-Sectional Surveys in the Jiangsu Province, China.
Zhu Y; Wang Y; Sun X; Li X
Int J Environ Res Public Health; 2019 Oct; 16(19):. PubMed ID: 31623326
[TBL] [Abstract][Full Text] [Related]
10. Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China.
Zhang Y; Wei Y; Li H; Chen Y; Guo Y; Han S; Shi L; Guan X
Pharmacoeconomics; 2022 Jul; 40(7):715-724. PubMed ID: 35764914
[TBL] [Abstract][Full Text] [Related]
11. The impact of an innovative payment method on medical expenditure, efficiency, and quality for inpatients with different types of medical insurance: evidence from a pilot city, China.
Lin K; Li Y; Yao Y; Xiong Y; Xiang L
Int J Equity Health; 2024 Jun; 23(1):115. PubMed ID: 38840102
[TBL] [Abstract][Full Text] [Related]
12. How government insurance coverage changed the utilization and affordability of expensive targeted anti-cancer medicines in China: an interrupted time-series study.
Diao Y; Qian J; Liu Y; Zhou Y; Wang Y; Ma H; Wang X; Luo R; Wagner A; Sun J; Liu Y
J Glob Health; 2019 Dec; 9(2):020702. PubMed ID: 31673344
[TBL] [Abstract][Full Text] [Related]
13. Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study.
Zhu H; Zhu J; Zhou Y; Shan L; Li C; Cui Y; Kang Z; Jiao M; Liu H; Gao L; Wu Q; Hao Y
Front Public Health; 2022; 10():921093. PubMed ID: 35844892
[TBL] [Abstract][Full Text] [Related]
14. Impact of public health insurance coverage of novel anticancer medication on medical expenditure and patient affordability in a provincial medical centre of China: a propensity score-matching analysis with the quasi-experimental design.
Diao Y; Lin M; Xu K; Huang J; Wu X; Li M; Sun J; Li H
BMJ Open; 2022 Feb; 12(2):e054713. PubMed ID: 35173004
[TBL] [Abstract][Full Text] [Related]
15. Price negotiation and pricing of anticancer drugs in China: An observational study.
Zhou J; Lan T; Lu H; Pan J
PLoS Med; 2024 Jan; 21(1):e1004332. PubMed ID: 38166148
[TBL] [Abstract][Full Text] [Related]
16. Inequity in healthcare needs, health service use and financial burden of medical expenditures in China: results from a consecutive household monitoring study in Jiangsu Province.
Jiang W; Xu X; Tang S; Xu L; Zhang Y; Elbers C; Cobelens F; Yan L
BMC Health Serv Res; 2019 Dec; 19(1):966. PubMed ID: 31842861
[TBL] [Abstract][Full Text] [Related]
17. Impact of the National Health Insurance Coverage Policy on the Utilisation and Accessibility of Innovative Anti-cancer Medicines in China: An Interrupted Time-Series Study.
Fang W; Xu X; Zhu Y; Dai H; Shang L; Li X
Front Public Health; 2021; 9():714127. PubMed ID: 34422752
[No Abstract] [Full Text] [Related]
18. The impacts of the National Medication Price-Negotiated Policy on the financial burden of cancer patients in Shandong province, China: an interrupted time series analysis.
Ding Y; Zheng C; Wei X; Zhang Q; Sun Q
BMC Public Health; 2022 Dec; 22(1):2363. PubMed ID: 36527037
[TBL] [Abstract][Full Text] [Related]
19. Catastrophic health expenditure and its determinants in households with lung cancer patients in China: a retrospective cohort study.
Sun CY; Shi JF; Fu WQ; Zhang X; Liu GX; Chen WQ; He J
BMC Cancer; 2021 Dec; 21(1):1323. PubMed ID: 34893037
[TBL] [Abstract][Full Text] [Related]
20. Trends in accessibility of negotiated targeted anti-cancer medicines in Nanjing, China: An interrupted time series analysis.
Liu Y; Yi H; Fang K; Bao Y; Li X
Front Public Health; 2022; 10():942638. PubMed ID: 35937254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
